Extended Data Fig. 8: Change in AKR1B10, TREM2 and CFHR4 protein levels in participants with MASH treated with semaglutide compared with protein levels in healthy volunteers in an independent real-world observational cohort.
a. Left-hand panel shows abundance of AKR1B10 from healthy individuals and those with MASH in the independent cohort. Center of boxplot is median, box boundary is first and third quantile, upper whisker is third quantile plus 1.5 IQR and lower whisker is first quantile minus 1.5 IQR, where IQR is third quantile minus first quantile (healthy, n = 89; MASH, n = 146). The right-hand panel shows the effect of semaglutide treatment on AKR1B10 levels in patients with MASH from a phase 2 trial population (semaglutide 0.1 mg [n = 80], semaglutide 0.2 mg [n = 78], semaglutide 0.4 mg [n = 82] and placebo [n = 80]). b and c, as for panel a but showing levels of TREM2 and CFHR2, respectively. Data are presented as mean + s.e.m. MASH, metabolic dysfunction-associated steatohepatitis; RFU, relative fluorescence units; s.e.m., standard error of the mean.
